ABBV-319
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dry Eye Syndrome
Conditions
Dry Eye Syndrome, Systemic Lupus Erythematosus
Trial Timeline
Aug 26, 2025 → Mar 1, 2029
NCT ID
NCT06977724About ABBV-319
ABBV-319 is a phase 1 stage product being developed by AbbVie for Dry Eye Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06977724. Target conditions include Dry Eye Syndrome, Systemic Lupus Erythematosus.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06977724 | Phase 1 | Recruiting |
| NCT05512390 | Phase 1 | Recruiting |
Competing Products
20 competing products in Dry Eye Syndrome